[1]王荣 马江卫.替勃龙联合唑来膦酸治疗绝经后 骨质疏松症的临床疗效[J].国际内分泌代谢杂志,2019,39(02):77-82,96.[doi:10.3760/cma.j.issn.1673-4157.2019.02.002]
　Wang Rong,Ma Jiangwei.Clinical effect of tibolone combined with zoledronic acid in the treatment of patients with postmenopausal osteoporosis[J].International Journal of Endocrinology and Metabolism,2019,39(02):77-82,96.[doi:10.3760/cma.j.issn.1673-4157.2019.02.002]
点击复制

替勃龙联合唑来膦酸治疗绝经后 骨质疏松症的临床疗效()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年02期
页码:
77-82,96
栏目:
论著
出版日期:
2019-03-20

文章信息/Info

Title:
Clinical effect of tibolone combined with zoledronic acid in the treatment of patients with postmenopausal osteoporosis
作者:
王荣1 马江卫2
1陕西省榆林市第一医院内分泌科 719000; 2陕西省榆林市第一医院骨一科 719000
Author(s):
Wang Rong1;  Ma Jiangwei2
1Department of Endocrinology, The First Hospital of Yulin City, Shanxi Province, Yulin 719000, China; 2Department of Orthopedics, The First Hospital of Yulin City, Shanxi Province, Yulin 719000, China
关键词:
替勃龙;  唑来膦酸;  绝经后骨质疏松;  骨转换标志物;  骨密度
Keywords:
Tibolone;  Zoledronic acid;  Postmenopausal osteoporosis;  Bone turnover makers;  Bone mineral density
DOI:
10.3760/cma.j.issn.1673-4157.2019.02.002
摘要:
目的 观察替勃龙联合唑来膦酸治疗绝经后骨质疏松症(PMOP)患者的临床疗效。方法 回顾性分析2014年1月至2017年1月陕西省榆林市第一医院就诊的PMOP患者120例,采用随机数字表法随机分为替勃龙联合唑来膦酸治疗组(A组),替勃龙治疗组(B组)及唑来膦酸治疗组(C组),每组40例。A组予以唑来膦酸 5 mg静脉滴注,每年1次,联合替勃龙 2.5 mg qd,1年后替勃龙减至维持量 1.25 mg qd,总疗程2年; B组予以替勃龙 2.5 mg qd,1年后减至维持量 1.25 mg qd,总疗程2年; C组予以唑来膦酸 5 mg静脉滴注,每年1次,总疗程2年。各组均于治疗第0、3、6、12、24个月进行视觉模拟评分(VAS)及血清Ⅰ型原胶原N-端前肽(P1NP)及血清Ⅰ型胶原羧基末端肽片段(β-CTX)的测定; 于治疗第0、6、12、24个月测定25羟维生素D(25OHD)、雌激素及卵泡刺激素(FSH); 于治疗第0、12、24个月采用双能X线吸收法测定腰椎1～4(L1～4)及右侧股骨颈骨密度; 并监测药物不良反应事件的发生率。结果 治疗第3、6、12、24个月A组及C组临床疼痛症状有效缓解,VAS较治疗前明显降低(F=66.236、104.766,P均<0.05),B组VAS无显著变化。治疗第6、12、24个月3组P1NP、β-CTX及25OHD水平较治疗前均得到明显改善(F=14.291～65.044,P均<0.05); 治疗第6、12、24个月A组P1NP、β-CTX水平降低优于其他两组(F=3.517～110.317,P均<0.05),且在治疗第3个月仅A组β-CTX水平显著改善(F=36.584,P<0.05)。治疗第12、24个月3组L1～4及右侧股骨颈骨密度值较治疗前均明显增加(F=13.455～77.341,P均<0.05); 治疗第24个月A组L1～4及右侧股骨颈骨密度值增加优于其他两组(F=13.958、10.759,P均<0.05); 与同组治疗12个月后相比,A组治疗24个月后L1～4及右侧股骨颈骨密度进一步增加(F=48.450、77.314,P均<0.05)。A组及B组在治疗后绝经相关症状显著改善,FSH水平降低(F=43.097、52.818,P均<0.05),但雌激素水平无明显变化。A组轻微的药物不良反应发生率高于其他两组(χ2=25.048,P<0.05),但无严重的药物不良反应事件发生。结论 替勃龙联合唑来膦酸治疗PMOP临床疗效显著,安全性高。
Abstract:
Objective To observe the clinical effect of tibolone combined with zoledronic acid in the treatment of patients with postmenopausal osteoporosis(PMOP).Methods A total of 120 cases of PMOP were collected from the First Hospital of Yulin City in Shanxi province from January 2014 to January 2017, and were randomly divided into tibolone combined with zoledronic acid therapy group(group A), tibolone therapy group(group B)and zoledroni acid group(group C), with 40 cases in each group, using the random number table method. Group A was treated with zoledronic acid 5 mg intravenous infusion once a year in combination with tibolone 2.5 mg qd, after 1 year tibolone was reduced to a maintenance dose of 1.25 mg qd for a total course of 2 years. Group B was received tibolone 2.5 mg qd alone, which was reduced to 1.25 mg qd after 1 year treatment, for a total course of 2 years. Group C was given zoledronic acid 5 mg intravenous infusion alone once a year for a total course of 2 years. The visual analogue scale(VAS), procollagen type 1 N-terminal peptide(P1NP), β cross-linked C-telopeptide of type 1 collagen(β-CTX)were detected at the 0, 3th, 6th, 12th, 24th month. 25-hydroxy-vitamin D(25OHD), estrogen and follicle stimulating hormone(FSH)were detected at the 0, 6th, 12th, 24th month. The bone mineral density of lumbar vertebra 1-4(L1-4)and right femoral neck were determined by dual-energy X-ray absorption method at 0, 12th and 24th month. The incidence of drug side effects was supervised.Results At the 3th, 6th, 12th, 24th month after treatment, the clinical pain symptom was effectively relieved and the VAS was significantly reduced(F=66.236, 104.766, all P<0.05)in both group A and C, however, there was no significant change of VAS in group B. At the 6th, 12th, 24th month after treatment, the levels of P1NP, β-CTX and 25OHD were significantly improved(F=14.291-65.044, all P<0.05)in all groups. At the 6th, 12th, 24th month after treatment, the decrease of P1NP and β-CTX in group A were much significant than those in other two groups(F=3.517-110.317, all P<0.05). The β-CTX level in group A was significantly improved at the 3th month after treatment(F=36.584, P<0.05). At the 12th, 24th month after treatment, bone mineral density of L1-4 and right femoral neck were increased(F=13.455-77.341, all P<0.05)in three groups. At the 24th month after treatment, bone mineral density of the L1-4 and right femoral neck of group A was better than that in other two groups(F=13.958, 10.759, all P<0.05). Compared with the same group at the 12th month after treatment, bone mineral density of the L1-4 and right femoral neck in group A was furtherly increased at the 24th month after treatment(F=48.450, 77.314, all P<0.05). After treatment, in group A and group B,the postmenopausal symptoms were significantly relieved and the FSH levels were significantly reduced(F=43.097, 52.818, all P<0.05), but there was no significant effect on estrogen level. The incidence of mild drug side effects in group A was higher than that in the other two groups(χ2=25.048, P<0.05), but the severe drug side effects were rarely observed.Conclusion The treatment of tibolone combined with zoledronic acid in patient with PMOP shows significant clinical effects and higher safety.

参考文献/References:

[1] Melton LJ 3rd,Chrischilles EA,Cooper C,et al.Perspective. How many women have osteoporosis?[J].J Bone Miner Res,1992,7(9):1005-1010.DOI:10.1002/jbmr.5650070902.
[2] Cauley JA.The determinants of fracture in men[J].J Musculoskelet Neuronal Interact,2002,2(3):220-221.
[3] Khosla S,Oursler MJ,Monroe DG.Estrogen and the skeleton[J].Trends Endocrinol Metab,2012,23(11):576-581.DOI:10.1016/j.tem.2012.03.008.
[4] Almeida M,Iyer S,Martin-Millan M,et al.Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual[J].J Clin Invest,2013,123(1):394-404.DOI:10.1172/JCI65910.
[5] Oursler MJ,Osdoby P,Pyfferoen J,et al.Avian osteoclasts as estrogen target cells[J].Proc Natl Acad Sci U S A,1991,88(15):6613-6617.
[6] Shevde NK,Bendixen AC,Dienger KM,et al.Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression[J].Proc Natl Acad Sci U S A,2000,97(14):7829-7834.DOI:10.1073/pnas.130200197.
[7] Srivastava S,Toraldo G,Weitzmann MN,et al.Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand(RANKL)-induced JNK activation[J].J Biol Chem,2001,276(12):8836-8840.DOI:10.1074/jbc.M010764200.
[8] Kousteni S,Bellido T,Plotkin LI,et al.Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity[J].Cell,2001,104(5):719-730.
[9] Kousteni S,Han L,Chen JR,et al.Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids[J].J Clin Invest,2003,111(11):1651-1664.DOI:10.1172/JCI17261.
[10] Almeida M,Han L,Martin-Millan M,et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids[J].J Biol Chem,2007,282(37):27285-27297.DOI:10.1074/jbc.M702810200.
[11] Feng J,Liu S,Ma S,et al.Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-κB signaling pathway[J].Acta Biochim Biophys Sin(Shanghai),2014,46(12):1024-1033.DOI:10.1093/abbs/gmu103.
[12] Nachtigall LE,李守柔.雌激素代替疗法与骨质疏松症的关系[J].国外医学(老年医学分册),1980,(2):25-27.
[13] 王峰,李振武,严锐峰,等.雌激素+黄体素联合常规方案治疗女性绝经后骨质疏松整的效果观察[J].中国药房,2016,27(2):237-239.DOI:10.6039/j.issn.1001-0408.
[14] 黎涛.雌激素联合抗骨质疏松药物治疗绝经后妇女骨质疏松症75例临床疗效分析[J].中国医药科学,2015,5(24):54-56.
[15] Cummings SR,Ettinger B,Delmas PD,et al.The effects of tibolone in older postmenopausal women[J].N Engl J Med,2008,359(7):697-708. DOI:10.1056/NEJMoa0800743.
[16] Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J].N Engl J Med,2007,356(18):1809-1822.DOI:10.1056/NEJMoa067312.
[17] Chao M,Hua Q,Yingfeng Z,et al.Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women[J].Pak J Med Sci,2013,29(6):1381138-1381144.
[18] 赵光,杨艳萍,沈霖.替勃龙对绝经后骨质疏松症患者骨密度及骨代谢指标的影响[J].中华骨质疏松和骨矿盐疾病杂志,2012,5(1):20-24. DOI:10.3969/j.issn.1674-2591.2012. 01.004.
[19] 苏凡,林静霞,吴利秋,等.阿仑膦酸钠与激素替代疗法治疗骨质疏松症的比较[J].中国组织工程研究,2016,20(46):6893-6898.DOI:10.3969/j.issn.2095-4344.2016.46.007.
[20] 张秀珍,宋利格,李红,等.阿伦膦酸钠对绝经后骨质疏松症患者骨密度、细胞因子及骨代谢指标的影响[J].中华内科杂志,2006,45(7):565-568.
[21] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):413-443.DOI:10.3969 /j.issn.1674-2591.2017.05. 002.
[22] 中华医学会妇产科学会绝经学组. 绝经期激素管理与激素补充治疗临床应用指南(2012版)[J].中华妇产科杂志,2013,48(10):795-799. DOI:10.3760/cma.j.issn.0529-567x. 2013.10.018.

备注/Memo

备注/Memo:
通信作者:马江卫,Email:mjw75@163.com
Corresponding author: Ma Jiangwei, Email: mjw75@163.com
更新日期/Last Update: 2019-03-20